Here's what we'll cover
Here's what we'll cover
Australia's Ozempic Numbers Reflect a Global Shift
If you've been watching the GLP-1 space, Australia's latest figures probably don't surprise you. But they are striking. The country has recorded a surge in Ozempic users that mirrors patterns seen across the US, UK, and Europe. Millions of people are now taking semaglutide in some form, and Australia's data shows that adoption is accelerating fast.
This isn't just a headline. It reflects a real shift in how patients and doctors are approaching type 2 diabetes, obesity, and metabolic health. Understanding what's driving these numbers, and what they mean for you as a patient, is worth taking seriously.
Why So Many People Are Turning to Semaglutide
Semaglutide works by mimicking a hormone called GLP-1 (glucagon-like peptide-1), which signals fullness, slows digestion, and helps regulate blood sugar. Clinical trials have shown that it can produce meaningful weight loss alongside its blood sugar benefits. The SUSTAIN and STEP trial programs, run by Novo Nordisk, demonstrated average weight reductions of 10-15% in people taking semaglutide for weight management.
Those results spread fast. Word of mouth, media coverage, and social media drove awareness far beyond the traditional diabetes patient population. By 2023 and 2024, prescriptions had outpaced supply in multiple countries, including Australia.
What the Australian Market Tells Us About Global Demand
Australia's Therapeutic Goods Administration (TGA) approved Ozempic for type 2 diabetes and later listed Wegovy for chronic weight management. The pattern closely followed the US FDA's approval timeline, and so did the demand spike.
When supply couldn't keep up with prescriptions, Australian health authorities took steps similar to those in the US, including rationing, supply alerts, and guidance discouraging off-label use for weight loss when stock was limited for diabetes patients.
The Australian experience is a useful case study. It shows what happens when a medication transitions from a specialized treatment into a mainstream option sought by a much broader population. Demand pressure affects everything from pharmacy stock to telehealth waitlists to pricing.
What This Means If You're Based in the US
Even if you're not in Australia, these global demand signals affect you. They influence Novo Nordisk's manufacturing scale-up decisions, compounding regulations, and the pace at which generic or biosimilar versions may enter the market. A tight global supply chain means staying informed about your own prescription pipeline is genuinely useful.
Supply Shortages: Are They Still a Concern?
For most of 2022 through 2024, Ozempic shortages were a real problem in the US and internationally. The FDA maintained Ozempic on its drug shortage list for extended periods, affecting patients who depended on it for diabetes management.
As of mid-2025, the supply situation has improved in the US, though it remains worth monitoring. Novo Nordisk has significantly expanded manufacturing capacity. The FDA removed semaglutide from the official shortage list in early 2025, which also triggered updated regulations around compounded semaglutide.
Here's a quick look at the timeline that shaped today's market:
The Real Cost of Ozempic: What Patients Actually Pay
One of the most common questions from people considering semaglutide is: what will this actually cost me? The answer depends on your insurance status, the dose you need, and whether you're using brand-name or alternative options.
In the US, brand-name Ozempic has a list price of approximately $935-$1,000 per month without insurance. Wegovy, the higher-dose version approved for weight loss, lists at around $1,350 per month. These prices are not what most insured patients pay, but uninsured or underinsured patients face the full cost.
Ways Patients Reduce Out-of-Pocket Costs
- Manufacturer savings cards. Novo Nordisk offers a savings program for eligible commercially insured patients, reducing costs significantly.
- Insurance coverage. Coverage varies widely. Many plans cover Ozempic for diabetes but not for weight loss.
- GLP-1 coupons and discount programs. Third-party discount platforms can reduce costs at the pharmacy counter.
- Provider programs. Some telehealth providers include medication support or sourcing assistance in their subscription fees.
You can explore current options on the GLP-1 Coupons page to compare what's available right now.
How Australia's Experience Compares to the US
Both countries use Ozempic (semaglutide 0.5mg-2mg) for type 2 diabetes and have separate approval pathways for the weight management indication under the Wegovy brand. But the cost and access structures differ meaningfully.
Australia's Pharmaceutical Benefits Scheme (PBS) has provided subsidized access for type 2 diabetes patients, which partly explains high uptake numbers. More people can afford to start and stay on the medication when cost is lower.
Tirzepatide Is Also Growing Fast
While the headlines focus on semaglutide, it's worth knowing that Mounjaro (tirzepatide) is following a similar adoption curve. Tirzepatide targets two hormone receptors (GLP-1 and GIP) and has shown even greater average weight loss in clinical trials than semaglutide alone.
The SURMOUNT-1 trial found that tirzepatide 15mg produced an average weight loss of around 22% of body weight. That's a meaningful difference for patients who haven't achieved their goals on semaglutide alone.
Tirzepatide is now approved in Australia and gaining rapid uptake globally. Providers who compare GLP-1 options are increasingly discussing both molecules with patients, especially those with higher weight loss targets or those who haven't responded well to semaglutide.
Choosing a Provider: What to Look For
The growth in GLP-1 prescriptions has come alongside a surge in telehealth providers offering prescriptions, monitoring, and ongoing support. The quality and cost of these services varies significantly.
When evaluating a provider, ask these questions before committing:
- Do they require baseline lab work and health history review? A responsible provider should screen for contraindications before prescribing.
- What does the ongoing monitoring look like? Regular check-ins matter for dose adjustment and side effect management.
- Is medication included in the subscription, or billed separately? Some services bundle medication; others charge it separately at pharmacy prices.
- What's the cancellation policy? Lock-in contracts can be costly if the medication doesn't work for you.
- Can they prescribe both semaglutide and tirzepatide? Flexibility to switch medications if needed is a practical advantage.
The Best Providers comparison page on GLP-1.com breaks down current telehealth options by cost, medication availability, and patient experience.
Side Effects and What the Surge Means for Patient Monitoring
As GLP-1 use scales up globally, post-market safety monitoring becomes increasingly important. Australia's TGA and the US FDA both collect adverse event data from real-world users, and large user populations generate more signal data that researchers can analyze.
Common side effects of semaglutide include nausea, vomiting, diarrhea, and constipation, especially during dose escalation. These are generally manageable with slow titration (gradual dose increases) and dietary adjustments.
Less common but more serious concerns, including rare cases of pancreatitis and discussions around thyroid risk, are monitored actively. The absolute risk for most patients remains low, but this is exactly why working with a qualified provider and not self-medicating is important.
More users globally means more data, and that data will continue to refine our understanding of who benefits most from these medications and who may need additional monitoring.
No waiting list. No insurance needed.
Frequently Asked Questions
How many people are using Ozempic in Australia?
Recent reports indicate that hundreds of thousands of Australians have been prescribed semaglutide (Ozempic or Wegovy), with the numbers growing rapidly year over year. Exact figures are periodically released by Australia's Pharmaceutical Benefits Scheme and health authorities, reflecting the medication's widespread uptake for both diabetes management and weight loss.
Is Ozempic available and covered in Australia?
Yes. Ozempic is TGA-approved and listed on Australia's Pharmaceutical Benefits Scheme (PBS) for type 2 diabetes, making it substantially subsidized for eligible patients. Wegovy, the higher-dose version for weight management, has also received TGA approval, though subsidy arrangements for that indication differ.
Why is Ozempic so popular worldwide right now?
Semaglutide has shown consistent results for blood sugar control and meaningful weight loss in large clinical trials. Combined with media attention and social media discussion, that evidence base drove demand well beyond the traditional diabetes patient population, creating a global wave of prescriptions.
Did Ozempic shortages in Australia affect patients?
Yes. Australia experienced supply shortages between 2022 and 2024, similar to the US and UK. Australian authorities issued guidance asking that available stock be prioritized for type 2 diabetes patients rather than used off-label for weight loss alone. Supply has since improved as manufacturing capacity expanded.
Is Ozempic the same as Wegovy?
Both Ozempic and Wegovy contain semaglutide, but they are different products with different approved doses and indications. Ozempic is approved for type 2 diabetes at doses up to 2mg weekly. Wegovy is approved specifically for chronic weight management at a 2.4mg weekly maintenance dose.
How does the cost of Ozempic in Australia compare to the US?
Australian patients with type 2 diabetes pay roughly AUD $30-$50 per month for subsidized Ozempic through the PBS. In the US, insured patients may pay as little as $25 per month with a savings card, but uninsured patients face list prices of approximately $935-$1,000 per month for brand-name Ozempic.
What This All Means for You
Australia's Ozempic numbers are more than a headline. They're evidence that GLP-1 medications have moved firmly into mainstream medicine, and that millions of people globally are navigating the same questions you may be asking right now: Is this right for me? Can I afford it? How do I find a trustworthy provider?
The global scale of semaglutide adoption has real practical consequences. Supply chains are more resilient than they were two years ago, but they're not immune to disruption. Costs remain high without insurance or subsidies, though more programs are available to help. And the growing number of providers, telehealth platforms, and medication options means that doing your homework before committing to a service is more important than ever.
A Few Things Worth Doing Before You Start
First, talk to your doctor or a qualified prescriber about whether semaglutide or tirzepatide is appropriate for your specific health situation. Both have clear inclusion and exclusion criteria, and a proper medical review matters.
Second, check what your insurance actually covers. Many plans cover Ozempic for diabetes but not for weight management. Knowing this upfront saves frustration later.
Third, compare your options. The landscape of GLP-1 providers has expanded significantly. Some offer bundled medication and coaching. Others are prescription-only platforms. Price, support quality, and medication availability differ across all of them.
The Bottom Line
The surge in Ozempic use globally, including the striking numbers coming out of Australia, reflects genuine clinical results. These medications work for many people. But scale brings new challenges: cost pressure, provider quality variation, and the need for informed patient decision-making.
GLP-1.com exists to help you cut through the noise. Whether you're comparing Ozempic and Wegovy, weighing semaglutide against Mounjaro, or trying to find a provider that fits your budget and needs, the tools are here.
Start with the Best Providers comparison to see current options side by side, or check the GLP-1 Coupons page to find savings before your next prescription fill. And as always, consult your physician before starting or changing any medication.